next generation sequencing

View All

MedTech News for Relievant, EarliTec, ReddyPort
Relievant Medsystems Launched Ablation System; Thermo Fisher’s Reproductive Health Assays; EarliTec’s Next-Generation EarliPoint Evaluation for ASD; FDA Cleared ReddyPort® Non-Invasive Ventilation Device; EndoTheia’s Novel Medical Device for Endoscopic Surgery; Neurolief’s MOOD Trial Interim Analysis

Relievant Medsystems Launched New Tools for its Ablation System On June 14, 2023, Relievant Medsystems announced that it launched its next-generation access instruments for the Intracept procedure. Chronic vertebrogenic low back pain is treated with Intracept, a minimally invasive, same-day, outpatient proced...

Find More

cancer-diagnostics-market-landscape
Cancer Diagnostic Market: Evaluating the Major Growth Factors and the Key Developments in the Domain

Cancer is a global burden, leading to a significant number of death and disabilities worldwide. In 2020, nearly one in six deaths were related to cancer. Breast cancer, lung cancer, colon and rectum cancer, and prostate cancer are some of the major cancer types, registering the highest number of cases globally. To ...

Find More

MedTech News and Update GE HealthCare, Medtronic, Nevro, Syntr Health Technologies, Devyser + Thermo Fisher Scientific, Smith+Nephew
GE HealthCare’s CARESCAPE Canvas Patient Monitoring Platform; Medtronic’s MiniMed™ 780G System; Nevro Enroll’s First Patient in PDN Sensory Study; Syntr Health Presents Data from Facial Fat Transfer Clinical Study; Devyser-Thermo Fisher Scientific Signs Agreement; Smith+Nephew Introduced Digital Tensioning Device

GE HealthCare’s CARESCAPE Canvas Patient Monitoring Platform Received FDA Clearance  On April 20, 2023, GE HealthCare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, received the US FDA 510(k) clearance for its CARESCAPE Canvas patient monitoring platform f...

Find More

minimal-residue-disease-mrd-testing-market
Minimal Residual Disease (MRD) Testing: A Path to Cure Cancer?

Measurable or Minimal Residual Disease (MRD) is a term often used when treating patients with blood cancers. MRD is a small number of cancer cells left in the body after cancer treatment, and these cells can potentially cause relapse in these patients. The number of remaining cells is often too small to cause any s...

Find More